Brookline initiated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics initiated with an Overweight at Piper Sandler
- Buy These 3 Penny Stocks Now, Say Five-Star Analysts
- Opus Genetics doses first participant in OPGx-BEST1 Phase 1/2 trial
- Promising Advancements in Opus Genetics’ Retinal Disease Platform Support Buy Rating
- Opus Genetics: Buy Rating Backed by Strong Financials, Regulatory Support, and Promising Study Progress